What’s Past Is Prologue: History of Nonalcoholic Fatty Liver Disease
Abstract
:Funding
Conflicts of Interest
References
- Lonardo, A.; Leoni, S.; Alswat, K.A.; Fouad, Y. History of nonalcoholic fatty liver disease. Int. J. Mol. Sci. 2020, 21, 5888. [Google Scholar] [CrossRef] [PubMed]
- Loomba, R.; Sanyal, A.J. The global NAFLD epidemic. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 686–690. [Google Scholar] [CrossRef] [PubMed]
- Younossi, Z.; Anstee, Q.M.; Marietti, M.; Hardy, T.; Henry, L.; Eslam, M.; George, J.; Bugianesi, E. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 2018, 15, 11–20. [Google Scholar] [CrossRef] [PubMed]
- Mantovani, A.; Scorletti, E.; Mosca, A.; Alisi, A.; Byrne, C.D.; Targher, G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism 2020, 30, 154170. [Google Scholar] [CrossRef] [PubMed]
- Ludwig, J.; Viggiano, T.R.; McGill, D.B.; Oh, B.J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 1980, 55, 434–438. [Google Scholar]
- Schaffner, F.; Thaler, H. Nonalcoholic fatty liver disease. Prog. Liver Dis. 1986, 8, 283–898. [Google Scholar]
- Marchesini, G.; Bugianesi, E.; Forlani, G.; Cerrelli, F.; Lenzi, M.; Manini, R.; Natale, S.; Vanni, E.; Villanova, N.; Melchionda, N.; et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37, 917–923. [Google Scholar] [CrossRef]
- Samuel, V.T.; Shulman, G.I. Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases. Cell Metab. 2018, 27, 22–41. [Google Scholar] [CrossRef] [Green Version]
- Stefan, N.; Häring, H.U.; Cusi, K. Non-alcoholic fatty liver disease: Causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019, 7, 313–324. [Google Scholar] [CrossRef]
- Targher, G.; Day, C.P.; Bonora, E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. Med. 2010, 363, 1341–1350. [Google Scholar] [CrossRef] [Green Version]
- Adams, L.A.; Anstee, Q.M.; Tilg, H.; Targher, G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017, 66, 1138–1153. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Byrne, C.D.; Targher, G. NAFLD as a driver of chronic kidney disease. J. Hepatol. 2020, 72, 785–801. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Byrne, C.D.; Targher, G. NAFLD: A multisystem disease. J. Hepatol. 2015, 62 (Suppl. 1), S47–S64. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yki-Järvinen, H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014, 2, 901–910. [Google Scholar] [CrossRef]
- Lonardo, A.; Nascimbeni, F.; Mantovani, A.; Targher, G. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? J. Hepatol. 2018, 68, 335–352. [Google Scholar] [CrossRef] [PubMed]
- Targher, G.; Byrne, C.D.; Lonardo, A.; Zoppini, G.; Barbui, C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J. Hepatol. 2016, 65, 589–600. [Google Scholar] [CrossRef] [Green Version]
- Mantovani, A.; Petracca, G.; Beatrice, G.; Tilg, H.; Byrne, C.D.; Targher, G. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: An updated meta-analysis of 501 022 adult individuals. Gut 2020. Gutjnl-2020-322572. [Google Scholar] [CrossRef]
- Eslam, M.; Newsome, P.N.; Sarin, S.K.; Anstee, Q.M.; Targher, G.; Romero-Gomez, M.; Zelber-Sagi, S.; Wai-Sun Wong, V.; Dufour, J.F.; Schattenberg, J.M.; et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J. Hepatol. 2020, 73, 202–209. [Google Scholar] [CrossRef]
- Targher, G.; Byrne, C.D. From nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease: Is it time for a change of terminology? Hepatoma Res. 2020, 6, 64. [Google Scholar] [CrossRef]
- Younossi, Z.M.; Rinella, M.E.; Sanyal, A.; Harrison, S.A.; Brunt, E.; Goodman, Z.; Cohen, D.E.; Loomba, R. From NAFLD to MAFLD: Implications of a premature change in terminology. Hepatology 2020. Available online: https://aasldpubs.onlinelibrary.wiley.com/doi/abs/10.1002/hep.31420 (accessed on 29 September 2020). [CrossRef]
- Tilg, H.; Effenberger, M. From NAFLD to MAFLD: When pathophysiology succeeds. Nat. Rev. Gastroenterol. Hepatol. 2020, 17, 387–388. [Google Scholar] [CrossRef] [PubMed]
- Cardoso, A.C.; de Figueiredo-Mendes, C.A.; Villela-Nogueira, C.; Sanyal, A.J. New drugs for non-alcoholic steatohepatitis. Liver Int. 2020, 40 (Suppl. 1), 96–101. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Targher, G.; Byrne, C.D.; Tilg, H. NAFLD and increased risk of cardiovascular disease: Clinical associations, pathophysiological mechanisms and pharmacological implications. Gut 2020, 69, 1691–1705. [Google Scholar] [CrossRef] [PubMed]
- Connelly, M.A.; Velez Rivera, J.; Guyton, J.R.; Siddiqui, M.S.; Sanyal, A.J. Review article: The impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2020, 52, 619–636. [Google Scholar] [CrossRef] [PubMed]
- Johnston, M.P.; Patel, J.; Byrne, C.D. Multi-drug approaches to NASH: What’s in the development pipeline? Expert Opin. Investig. Drugs 2020, 29, 143–150. [Google Scholar] [CrossRef] [PubMed]
- Wieland, A.C.; Mettler, P.; McDermott, M.T.; Crane, L.A.; Cicutto, L.C.; Bambha, K.M. Low awareness of nonalcoholic fatty liver disease among patients at high metabolic risk. J. Clin. Gastroenterol. 2015, 49, e6–e10. [Google Scholar] [CrossRef] [PubMed]
- Alemany-Pagès, M.; Moura-Ramos, M.; Araújo, S.; Macedo, M.P.; Ribeiro, R.T.; do Ó., D.; Ramalho-Santos, J.; Azul, A.M. Insights from qualitative research on NAFLD awareness with a cohort of T2DM patients: Time to go public with insulin resistance? BMC Public Health 2020, 20, 1142. [Google Scholar] [CrossRef]
© 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Targher, G. What’s Past Is Prologue: History of Nonalcoholic Fatty Liver Disease. Metabolites 2020, 10, 397. https://doi.org/10.3390/metabo10100397
Targher G. What’s Past Is Prologue: History of Nonalcoholic Fatty Liver Disease. Metabolites. 2020; 10(10):397. https://doi.org/10.3390/metabo10100397
Chicago/Turabian StyleTargher, Giovanni. 2020. "What’s Past Is Prologue: History of Nonalcoholic Fatty Liver Disease" Metabolites 10, no. 10: 397. https://doi.org/10.3390/metabo10100397